Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670008 | 0.65 | KMT2A (0.35) | GAAKMT2AMAPTKDM4ENPC1 | |
| SCHEMBL670495 | 0.64 | KDM4E (0.59) | GAAKMT2AMAPTKDM4ENPC1 | |
| SCHEMBL669754 | 0.64 | MAPT (0.33) | GAAKMT2AMAPTKDM4ENPC1 | |
| SCHEMBL5507000 | 0.61 | DHODH (0.47) | ALDH1A1DHODH | |
| Acridine SCHEMBL27894463 | 0.60 | MAPT (0.68) | GAAKMT2AMAPTKDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL28248902 | 0.58 | ALDH1A1 (0.47) | GAAKMT2AMAPTKDM4ENPC1 | |
| SCHEMBL3639840 | 0.57 | ATM (0.63) | NPC1IDO1 | |
| SCHEMBL9628083 | 0.57 | MAPT (0.41) | GAAKMT2AMAPTKDM4ENPC1 | |
| SCHEMBL11547422 | 0.57 | SRC (0.56) | GAAKMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL3387991 | 0.57 | KMT2A (0.62) | KMT2AMAPTALDH1A1GLAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073920-B2 | Substituted dibenzonaphthyridines, pharmaceutical uses thereof and processes therfor | PURDUE RESEARCH FOUNDATION (US) | 2015-07-07 | — | — | US | disclosed |
| US-20130143878-A1 | SUBSTITUTED DIBENZONAPHTHYRIDINES, PHARMACEUTICAL USES THEREOF AND PROCESSES THERFOR | PURDUE RESEARCH FOUNDATION (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2012024437-A1 | SUBSTITUTED DIBENZONAPHTHYRIDINES, PHARMACEUTICAL USES THEREOF AND PROCESSES THERFOR | PURDUE RESEARCH FOUNDATION (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143878-A1 | SUBSTITUTED DIBENZONAPHTHYRIDINES, PHARMACEUTICAL USES THEREOF AND PROCESSES THERFOR | KRAS, QDPR, BTD | GAA 509/4885KMT2A 3863/4885MAPT 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.